Basilea updates on isavuconazole development

17 July 2013

Switzerland-based Basilea Pharmaceutica Ltd. (SIX: BSLN) provided an update today (July 17) on the Phase III program with the novel antifungal isavuconazole that is being developed in collaboration with Japanese drug major Astellas Pharma (TYO: 4503), under a 2010 deal that has the potential to earn $512 million for the Swiss firm (The Pharma Letter February 24, 2010).

Top-line data from the SECURE and VITAL Phase III studies are on track to be available in the second half of 2013. The SECURE registration study evaluates the safety and efficacy of once-daily isavuconazole versus twice-daily voriconazole for the primary treatment of life-threatening invasive fungal disease caused by Aspergillus species. The VITAL study is an open-label Phase III study in the treatment of aspergillosis patients with pre-existing renal impairment or with invasive fungal disease caused by emerging and often fatal fungi.

Initial regulatory filing likely in first part of 2014

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >